Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84


Reversal of tumor immune inhibition using a chimeric cytokine receptor.

Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF.

Mol Ther. 2014 Jun;22(6):1211-20. doi: 10.1038/mt.2014.47. Epub 2014 Mar 20.


Boolean immunotherapy: reversal of fortune.

Morgan RA.

Mol Ther. 2014 Jun;22(6):1073-4. doi: 10.1038/mt.2014.75. No abstract available.


Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.

Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G.

Clin Cancer Res. 2014 Jan 1;20(1):131-9. doi: 10.1158/1078-0432.CCR-13-1016. Epub 2013 Oct 4. Erratum in: Clin Cancer Res. 2014 Aug 15;20(16):4413.


Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes.

Hunter MR, Prosser ME, Mahadev V, Wang X, Aguilar B, Brown CE, Forman SJ, Jensen MC.

Mol Immunol. 2013 Nov;56(1-2):1-11. doi: 10.1016/j.molimm.2013.03.021. Epub 2013 Apr 27.


Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Yvon E, Ahmed N.

Mol Ther. 2013 Nov;21(11):2087-101. doi: 10.1038/mt.2013.185. Epub 2013 Aug 13. Erratum in: Mol Ther. 2014 May;22(5):1063. Gottachalk, Stephen [corrected to Gottschalk, Stephen].


Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

Blood. 2002 Nov 1;100(9):3155-63. Erratum in: Blood. 2003 May 15;101(10):3808.


Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.

Spear P, Barber A, Rynda-Apple A, Sentman CL.

J Immunol. 2012 Jun 15;188(12):6389-98. doi: 10.4049/jimmunol.1103019. Epub 2012 May 14. Erratum in: J Immunol. 2014 Aug 1;193(3):1513.


Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.

Wang W, Ma Y, Li J, Shi HS, Wang LQ, Guo FC, Zhang J, Li D, Mo BH, Wen F, Liu T, Liu YT, Wang YS, Wei YQ.

Gene Ther. 2013 Oct;20(10):970-8. doi: 10.1038/gt.2013.19. Epub 2013 May 2.


Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.

Roychowdhury S, May KF Jr, Tzou KS, Lin T, Bhatt D, Freud AG, Guimond M, Ferketich AK, Liu Y, Caligiuri MA.

Cancer Res. 2004 Nov 1;64(21):8062-7.


A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.

Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, Cerutti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

Cancer Gene Ther. 2004 May;11(5):371-9.


Tumor ablation by gene-modified T cells in the absence of autoimmunity.

Wang LX, Westwood JA, Moeller M, Duong CP, Wei WZ, Malaterre J, Trapani JA, Neeson P, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2010 Dec 1;70(23):9591-8. doi: 10.1158/0008-5472.CAN-10-2884. Epub 2010 Nov 23.


HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.

Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S.

Clin Cancer Res. 2010 Jan 15;16(2):474-85. doi: 10.1158/1078-0432.CCR-09-1322. Epub 2010 Jan 12.


A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.

Yang S, Archer GE, Flores CE, Mitchell DA, Sampson JH.

Cancer Immunol Immunother. 2013 Nov;62(11):1649-62. doi: 10.1007/s00262-013-1464-0. Epub 2013 Aug 27.


Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo.

Perret R, Ronchese F.

Eur J Immunol. 2008 Oct;38(10):2886-95. doi: 10.1002/eji.200838483.


T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B.

Blood. 2009 Jun 18;113(25):6392-402. doi: 10.1182/blood-2009-03-209650. Epub 2009 Apr 17.


CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ.

Cancer Res. 2006 Nov 15;66(22):10995-1004.


Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G.

Blood. 2007 Oct 15;110(8):2793-802. Epub 2007 Jul 17.


Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

Hombach AA, Rappl G, Abken H.

Mol Ther. 2013 Dec;21(12):2268-77. doi: 10.1038/mt.2013.192. Epub 2013 Aug 28.


Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.

Zhang T, Sentman CL.

Cancer Res. 2011 Mar 15;71(6):2066-76. doi: 10.1158/0008-5472.CAN-10-3200. Epub 2011 Jan 31.


Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.

Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.

J Hematol Oncol. 2013 May 9;6:33. doi: 10.1186/1756-8722-6-33.

Items per page

Supplemental Content

Support Center